Calithera Biosciences Inc (CALA) Position Cut by Northern Trust Corp

Northern Trust Corp trimmed its holdings in Calithera Biosciences Inc (NASDAQ:CALA) by 3.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 325,603 shares of the biotechnology company’s stock after selling 10,854 shares during the quarter. Northern Trust Corp’s holdings in Calithera Biosciences were worth $1,628,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of CALA. Bank of New York Mellon Corp grew its holdings in Calithera Biosciences by 17.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 161,982 shares of the biotechnology company’s stock worth $810,000 after buying an additional 24,343 shares in the last quarter. Alambic Investment Management L.P. grew its holdings in Calithera Biosciences by 613.4% in the 2nd quarter. Alambic Investment Management L.P. now owns 263,374 shares of the biotechnology company’s stock worth $1,317,000 after buying an additional 226,456 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Calithera Biosciences by 67.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 792,300 shares of the biotechnology company’s stock worth $3,962,000 after buying an additional 319,906 shares in the last quarter. Federated Investors Inc. PA lifted its position in Calithera Biosciences by 32.8% in the second quarter. Federated Investors Inc. PA now owns 1,888,900 shares of the biotechnology company’s stock worth $9,445,000 after purchasing an additional 466,700 shares during the period. Finally, BlackRock Inc. lifted its position in Calithera Biosciences by 3.6% in the second quarter. BlackRock Inc. now owns 3,346,321 shares of the biotechnology company’s stock worth $16,731,000 after purchasing an additional 117,290 shares during the period. 52.38% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have recently commented on CALA shares. ValuEngine upgraded Calithera Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, October 12th. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research report on Tuesday, October 23rd. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $9.88.

Shares of NASDAQ:CALA opened at $4.93 on Monday. Calithera Biosciences Inc has a one year low of $4.05 and a one year high of $10.70. The firm has a market cap of $187.96 million, a PE ratio of -5.87 and a beta of 2.35.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 31.73%. Sell-side analysts forecast that Calithera Biosciences Inc will post -1.46 earnings per share for the current fiscal year.

WARNING: “Calithera Biosciences Inc (CALA) Position Cut by Northern Trust Corp” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2018/12/03/calithera-biosciences-inc-cala-position-cut-by-northern-trust-corp.html.

Calithera Biosciences Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Featured Article: Asset Allocation, Balancing Your Investments

Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences Inc (NASDAQ:CALA).

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit